These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 30056534)

  • 41. [Frontotemporal dementia and schizophrenia in later life: a comparison of executive and general cognitive functioning].
    Sanders F; Smeets-Janssen MM; Meesters PD; van der Vlies AE; Kerssens CJ; Pijnenburg YA
    Tijdschr Psychiatr; 2012; 54(5):409-17. PubMed ID: 22588955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit Schizophrenia.
    Kanchanatawan B; Hemrungrojn S; Thika S; Sirivichayakul S; Ruxrungtham K; Carvalho AF; Geffard M; Anderson G; Maes M
    Mol Neurobiol; 2018 Jun; 55(6):5184-5201. PubMed ID: 28875464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?
    Anderson VM; McIlwain ME; Kydd RR; Russell BR
    Psychiatry Res; 2015 Dec; 230(3):811-8. PubMed ID: 26564550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship of affect recognition with psychopathology and cognitive performance in schizophrenia.
    Bozikas VP; Kosmidis MH; Anezoulaki D; Giannakou M; Karavatos A
    J Int Neuropsychol Soc; 2004 Jul; 10(4):549-58. PubMed ID: 15327733
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Breakdown of the Paracellular Tight and Adherens Junctions in the Gut and Blood Brain Barrier and Damage to the Vascular Barrier in Patients with Deficit Schizophrenia.
    Maes M; Sirivichayakul S; Kanchanatawan B; Vodjani A
    Neurotox Res; 2019 Aug; 36(2):306-322. PubMed ID: 31077000
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuropsychological correlates of reality distortion in schizophrenic patients.
    Rocca P; Castagna F; Marchiaro L; Rasetti R; Rivoira E; Bogetto F
    Psychiatry Res; 2006 Nov; 145(1):49-60. PubMed ID: 17070602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased Eotaxin and MCP-1 Levels in Serum from Individuals with Periodontitis and in Human Gingival Fibroblasts Exposed to Pro-Inflammatory Cytokines.
    Boström EA; Kindstedt E; Sulniute R; Palmqvist P; Majster M; Holm CK; Zwicker S; Clark R; Önell S; Johansson I; Lerner UH; Lundberg P
    PLoS One; 2015; 10(8):e0134608. PubMed ID: 26241961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigating the association between neurocognition and psychosis in bipolar disorder: further evidence for the overlap with schizophrenia.
    Jabben N; Arts B; Krabbendam L; van Os J
    Bipolar Disord; 2009 Mar; 11(2):166-77. PubMed ID: 19267699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: studies in schizophrenia and bipolar disorder.
    Jabben N; Arts B; van Os J; Krabbendam L
    J Clin Psychiatry; 2010 Jun; 71(6):764-74. PubMed ID: 20122370
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Executive functioning during full and partial remission (positive and negative symptomatic remission) of schizophrenia.
    Braw Y; Benozio A; Levkovitz Y
    Schizophr Res; 2012 Dec; 142(1-3):122-8. PubMed ID: 23127380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Motivated to do well: an examination of the relationships between motivation, effort, and cognitive performance in schizophrenia.
    Foussias G; Siddiqui I; Fervaha G; Mann S; McDonald K; Agid O; Zakzanis KK; Remington G
    Schizophr Res; 2015 Aug; 166(1-3):276-82. PubMed ID: 26008882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional neuroimaging abnormalities in youth with psychosis spectrum symptoms.
    Wolf DH; Satterthwaite TD; Calkins ME; Ruparel K; Elliott MA; Hopson RD; Jackson CT; Prabhakaran K; Bilker WB; Hakonarson H; Gur RC; Gur RE
    JAMA Psychiatry; 2015 May; 72(5):456-65. PubMed ID: 25785510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognitive and functional deficits in people with schizophrenia: Evidence for accelerated or exaggerated aging?
    Harvey PD; Rosenthal JB
    Schizophr Res; 2018 Jun; 196():14-21. PubMed ID: 28506706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of Dystrobrevin-Binding Protein 1 Polymorphisms with Sustained Attention and Set-Shifting in Schizophrenia Patients.
    Bakanidze G; Brandl EJ; Hutzler C; Aurass F; Onken S; Rapp MA; Puls I
    Neuropsychobiology; 2016; 74(1):41-47. PubMed ID: 27798936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Magnitude of impact of executive functioning and IQ on episodic memory in Schizophrenia.
    Kopald BE; Mirra KM; Egan MF; Weinberger DR; Goldberg TE
    Biol Psychiatry; 2012 Mar; 71(6):545-51. PubMed ID: 22265665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Electrophysiological examination of Formal Thought Disorder in schizophrenia.
    Ray D; Ram D
    Asian J Psychiatr; 2012 Dec; 5(4):327-38. PubMed ID: 23174441
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurocognitive impairments in individuals at ultra-high risk for psychosis: Who will really convert?
    Bang M; Kim KR; Song YY; Baek S; Lee E; An SK
    Aust N Z J Psychiatry; 2015 May; 49(5):462-70. PubMed ID: 25425742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relation between jumping to conclusions and cognitive functioning in people with schizophrenia in contrast with healthy participants.
    Ochoa S; Haro JM; Huerta-Ramos E; Cuevas-Esteban J; Stephan-Otto C; Usall J; Nieto L; Brebion G
    Schizophr Res; 2014 Oct; 159(1):211-7. PubMed ID: 25112159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metamemory in schizophrenia: retrospective confidence ratings interact with neurocognitive deficits.
    Eifler S; Rausch F; Schirmbeck F; Veckenstedt R; Mier D; Esslinger C; Englisch S; Meyer-Lindenberg A; Kirsch P; Zink M
    Psychiatry Res; 2015 Feb; 225(3):596-603. PubMed ID: 25530415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.
    Jarskog LF; Pedersen CA; Johnson JL; Hamer RM; Rau SW; Elliott T; Penn DL
    Schizophr Res; 2017 Jul; 185():88-95. PubMed ID: 28094169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.